JF
IBRX icon

Jump Financial’s ImmunityBio IBRX Stock Holding History

Jump Financial’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-302,700
Closed -$2.32M – 2223
2026
Q1 		$2.32M Buy
302,700
+292,168
+2,774% +$2M 0.03% 599
2025
Q4 		$20.9K Buy
+10,532
New +$23.9K ﹤0.01% 1882
2023
Q3 		– Sell
-22,635
Closed -$62.9K – 2020
2023
Q2 		$62.9K Buy
+22,635
New +$64K ﹤0.01% 1712
2023
Q1 		– Sell
-16,900
Closed -$85.7K – 1789
2022
Q4 		$85.7K Buy
+16,900
New +$92.8K ﹤0.01% 1447
2022
Q2 		– Sell
-21,900
Closed -$123K – 1797
2022
Q1 		$123K Buy
21,900
+10,940
+100% +$67.1K 0.01% 1389
2021
Q4 		$66K Sell
10,960
-118,640
-92% -$891K ﹤0.01% 1279
2021
Q3 		$1.26M Buy
129,600
+13,857
+12% +$152K 0.09% 245
2021
Q2 		$1.65M Buy
115,743
+91,305
+374% +$1.51M 0.16% 153
2021
Q1 		$580K Buy
+24,438
New +$634K 0.05% 364
2020
Q4 		– Sell
-44,500
Closed -$309K – 1047
2020
Q3 		$309K Buy
+44,500
New +$444K 0.06% 485

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jump Financial's IBRX Position: Q2 2026 in Review

Jump Financial sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 302,700 shares — an estimated $2.32M sold.

Jump Financial first reported a position in IBRX in Q3 2020 and held it in 10 quarters. The position peaked at $2.32M in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Jump Financial reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
  • Jump Financial sold 302,700 ImmunityBio shares in Q2 2026, an estimated $2.32M.
  • Jump Financial first reported a position in ImmunityBio in Q3 2020 and held it in 10 quarters.
  • Jump Financial's ImmunityBio position peaked at $2.32M in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.